{"id":11546,"date":"2021-06-17T14:49:48","date_gmt":"2021-06-17T14:49:48","guid":{"rendered":"https:\/\/www.mymsd.ch\/de\/?page_id=11546"},"modified":"2025-05-22T13:24:19","modified_gmt":"2025-05-22T13:24:19","slug":"best-treatment-first","status":"publish","type":"page","link":"https:\/\/www.mymsd.ch\/it\/best-treatment-first\/","title":{"rendered":"Il miglior trattamento"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1500\" height=\"611\" src=\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png\" alt=\"\" class=\"wp-image-9002\" srcset=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2021\/06\/banner_campaign_BTF_de.png 1500w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2021\/06\/banner_campaign_BTF_de.png?resize=300,122 300w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2021\/06\/banner_campaign_BTF_de.png?resize=768,313 768w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2021\/06\/banner_campaign_BTF_de.png?resize=1024,417 1024w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2021\/06\/banner_campaign_BTF_de.png?resize=320,130 320w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2021\/06\/banner_campaign_BTF_de.png?resize=120,49 120w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2021\/06\/banner_campaign_BTF_de.png?resize=1400,570 1400w\" sizes=\"auto, (max-width: 1500px) 100vw, 1500px\" \/><\/figure>\n\n\n\n<nav class=\"wp-block-mconnect-theme-grid \">\n\t<ul class=\"is-grid-layout has-columns has-two-columns has-center-vertical-alignment\" >\n\t\t\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<figure class=\"wp-block-image size-full\" id=\"backtop\"><img decoding=\"async\" src=\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/campaign_BTF_57_de.png\" alt=\"Grafik_Lungenkrebs\" class=\"wp-image-9003\" \/><\/figure>\n\n\t<\/div>\n<\/li>\n\n\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" src=\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/campaign_BTF_half_de.png\" alt=\"Grafik_NSCLC\" class=\"wp-image-9004\" \/><\/figure>\n\n\t<\/div>\n<\/li>\n\n\t<\/ul>\n<\/nav>\n\n\n\n<h2 class=\"wp-block-heading mhh-mcn-v1-heading--center mhh-mcn-v1-heading mhh-mcn-v1-heading--05e21914da6a45263cb52c577a0d3192\"><strong>LE IMMUNOTERAPIE MODIFICANO I PARADIGMI DI TRATTAMENTO NEI PAZIENTI CON NSCLC AVANZATO<\/strong><\/h2>\n\n\n\n<nav class=\"wp-block-mconnect-theme-grid \">\n\t<ul class=\"is-grid-layout has-columns has-two-columns has-center-vertical-alignment\" >\n\t\t\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<p class=\"has-text-align-justify mhh-mcn-v1-paragraph--justify  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--fa53c20e454166d5fda1d19dbc39dc5a\">Le immunoterapie mirate in combinazione con chemioterapia hanno dimostrato, rispetto alla sola chemioterapia, una maggiore sopravvivenza complessiva (overall survival, OS) e sopravvivenza libera da progressione (progression-free survival, PFS)<sup>5<\/sup>, laddove gli studi hanno indicato che gli inibitori del checkpoint immunitario associati alla chemioterapia come&nbsp;<strong>nuova terapia standard<\/strong>&nbsp;devono essere presi in considerazione per i pazienti con NSCLC metastatico con wild type.<sup>6,7<\/sup><\/p>\n\n\t<\/div>\n<\/li>\n\n\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" src=\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/campaign_BTF_charts_de.png\" alt=\"Grafik_Sterberisiko und Risiko f\u00fcr Progression\" class=\"wp-image-9005\" \/><figcaption class=\"wp-element-caption\">Meta-analisi di 8 studi (n=4646) in pazienti con NSCLC avanzato senza istologia squamosa (71%) e NSCLC con istologia squamosa (29%) condotta a ottobre 2018. I pazienti sono stati randomizzati a ricevere la chemioterapia di prima linea pi\u00f9 un inibitore del checkpoint anti-PD-1 o anti-PD-L1 rispetto alla chemioterapia di prima linea.<sup>5<\/sup><\/figcaption><\/figure>\n\n\t<\/div>\n<\/li>\n\n\t<\/ul>\n<\/nav>\n\n\n\n<section class=\"wp-block-mconnect-theme-section has-light-grey-background-color has-background sub__entry__content wp-block-mconnect-theme-section--align-full has-red-border-color\">\n\t<div class=\"mhh-mcn-container\">\n\t\t\n\n<nav class=\"wp-block-mconnect-theme-grid \">\n\t<ul class=\"is-grid-layout has-columns has-two-columns has-center-vertical-alignment\" >\n\t\t\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<figure class=\"wp-block-image size-full\"><a href=\"https:\/\/players.brightcove.net\/1905768940001\/meAxH3mZK_default\/index.html?videoId=6150234385001\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" src=\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/09\/campaign_BTF_vid_image.png\" alt=\"\" class=\"wp-image-25821\" \/><\/a><\/figure>\n\n\t<\/div>\n<\/li>\n\n\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<figure class=\"wp-block-image alignleft size-large\"><img decoding=\"async\" src=\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/09\/cappuzzo_de.png?w=603\" alt=\"\" class=\"wp-image-26252\" \/><\/figure>\n\n\n\n<p class=\"   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--64edad0d362953ff6bb5d7e4c8c70c80\">Il dott. Cappuzzo, direttore del dipartimento di Oncologia ed Ematologia della AUSL della Romagna-Ravenna, Italia, parla dell&#8217;impiego di un trattamento pi\u00f9 efficace come prima linea e fa notare che \u00e8 importante soprattutto per i pazienti affetti da carcinoma polmonare, poich\u00e9 non possiamo essere sicuri che i pazienti riescano ad arrivare fino alla terapia di seconda linea per ricevere un ulteriore trattamento.<\/p>\n\n\t<\/div>\n<\/li>\n\n\t<\/ul>\n<\/nav>\n\n    <\/div>\n<\/section>\n\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.mymsd.ch\/it\/best-treatment-first-keytruda\/\">ISCRIVERSI PER SAPERNE DI PI\u00d9<\/a><\/div>\n<\/div>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-css-opacity\" \/>\n\n\n\n<h5 class=\"wp-block-heading  mhh-mcn-v1-heading mhh-mcn-v1-heading--cfeb12b31b29878f967e55d5cec4bd18\"><strong><em><span class=\"has-inline-color has-grey-color\">Note a pi\u00e8 di pagina<\/span><\/em><\/strong><\/h5>\n\n\n\n<p class=\"has-text-align-justify has-negative-1-font-size mhh-mcn-v1-paragraph--justify  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--a0b6f4324823796a531208e6ba84b06b\"><em><span class=\"has-inline-color has-grey-color\"><sup>*<\/sup>Pazienti che dopo il trattamento di prima linea al platino hanno ricevuto un trattamento di seconda linea per via di un nuovo carcinoma del polmone non a piccole cellule in stadio IIIB\/IV nel periodo antecedente all&#8217;immunoterapia (dal 2007 a met\u00e0 2013).1 Gli studi non hanno presentato un&#8217;eterogeneit\u00e0 significativa. Il gruppo con PD-L1 (1-49) basso ha mostrato un&#8217;eterogeneit\u00e0 significativa (p=0,06) tra il tipo di medicamento e l&#8217;efficacia: la combinazione di chemioterapia pi\u00f9 pembrolizumab ha mostrato benefici in termini di OS (HR, 0,56; IC al 95% 0,40-0,78; P &lt;0,00007), diversamente dagli studi su atezolizumab come terapia di base (HR, 0,92; IC al 95% 0,62-1,37; P &lt;0,69).&nbsp;<sup>\u00a7<\/sup>I valori P erano bilaterali e nominali<\/span><\/em><\/p>\n\n\n\n<h5 class=\"wp-block-heading  mhh-mcn-v1-heading mhh-mcn-v1-heading--0a0ffc9363b230d3110f0768a29ec434\"><strong><em><span class=\"has-inline-color has-grey-color\">Abbreviazioni<\/span><\/em><\/strong><\/h5>\n\n\n\n<p class=\"has-text-align-justify has-negative-1-font-size mhh-mcn-v1-paragraph--justify  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--a3f0b38d244ccd81e58cc198226b021d\"><em><span class=\"has-inline-color has-grey-color\">EI: effetto indesiderato; ALK: chinasi del linfoma anaplastico; BICR: revisione centrale indipendente in cieco (blinded independent central review);<br>IC: intervallo di confidenza; EGFR: recettore del fattore di crescita dell&#8217;epidermide (epidermal growth factor receptor); HR: tasso di rischio (Hazard Ratio); HRQoL: qualit\u00e0 della vita legata alla salute (health-related quality-of-life); LS: valore quadratico medio minimo dopo HRQoL; NR: non raggiunto (not reached); NCCN: National Comprehensive Cancer Network; NSCLC: carcinoma polmonare non a piccole cellule (non-small cell lung cancer); ORR: tasso di risposta globale (overall response rate); OS: sopravvivenza complessiva (overall survival); PD-L1: ligando di morte cellulare programmata 1;<br>PFS: sopravvivenza libera da progressione (progression-free survival); Q3W: ogni 3 settimane; QoL: qualit\u00e0 della vita (quality of life).<\/span><\/em><\/p>\n\n\n\n<h5 class=\"wp-block-heading  mhh-mcn-v1-heading mhh-mcn-v1-heading--d3d168cb06373c4538780f02654b4d1f\"><strong><em><span class=\"has-inline-color has-grey-color\">Fonti<\/span><\/em><\/strong><\/h5>\n\n\n\n<ol class=\"wp-block-list has-negative-1-font-size\">\n<li><mark class=\"has-inline-color has-grey-color\"><em>Arunachalam A, et al. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2018;19:e783-e799.<\/em><\/mark><\/li>\n\n\n\n<li><mark class=\"has-inline-color has-grey-color\"><em>Gadgeel S, et al. Updated Analysis From KEYNOTE-189: Pembrolizumab Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer [pubblicato online prima della versione stampata il 9 marzo 2020]. J Clin Oncol. doi:10.1200\/JC0.19.03136.<\/em><\/mark><\/li>\n\n\n\n<li><mark class=\"has-inline-color has-grey-color\"><em>Paz-Ares L, et al. Pembrolizumab Plus Chemotherapy in Metastatic Squamous NSCLC: Final Analysis and Progression After the Next Line of Therapy (PFS2) in KEYNOTE-407. Poster LBA852, presentato al congresso della Societ\u00e0 Europea di Oncologia Medica (ESMO); 27 settembre \u2013 1 ottobre 2019; Barcellona, Spagna.<\/em><\/mark><\/li>\n\n\n\n<li><mark class=\"has-inline-color has-grey-color\"><em>National Cancer Institute. Cancer Stat Facts: Lunch and Bronchus Cancer, 2020.<br>Disponibile al link:\u00a0<a href=\"https:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html<\/a>\u00a0Accesso: aprile 2020.<\/em><\/mark><\/li>\n\n\n\n<li><mark class=\"has-inline-color has-grey-color\"><em>Addeo A, et al. Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis. Front Oncol. 2019 16;9:264.<\/em><\/mark><\/li>\n\n\n\n<li><mark class=\"has-inline-color has-grey-color\"><em>Planchard D, et al. Metastatic Non-small Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Annals of Oncology 29(supplement 4): iv192-iv237, 2018.<\/em><\/mark><\/li>\n\n\n\n<li><mark class=\"has-inline-color has-grey-color\"><em>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>\u00ae<\/sup>) for Non-Small Cell Lung Cancer. NCCN Evidence Block<sup>\u2122<\/sup>. Versione 1.2020.\u00a0<sup>\u00a9<\/sup>\u00a0National Comprehensive Cancer Network, Inc. 2019. Tutti i diritti riservati. Accesso: aprile 2020. Per visualizzare la versione pi\u00f9 attuale e completa delle direttive, visiti NCCN.org.<\/em><\/mark><\/li>\n\n\n\n<li><mark class=\"has-inline-color has-grey-color\"><em>Garassino M, et al. Patient-reported Outcomes Following Pembrolizumab or Placebo Plus Pemetrexed and Platinum in Patients With Previously Untreated, Metastatic, Non-Squamous Non-Small-Cell Lung Cancer (KEYNOTE-189): A Multi Centre, Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. Lancet Oncol. 2020 21(3):387-397.<\/em><\/mark><\/li>\n\n\n\n<li><mark class=\"has-inline-color has-grey-color\"><em>Mazieres J, et al. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020 Jan 20;38(3):271-280.<\/em><\/mark><\/li>\n\n\n\n<li><mark class=\"has-inline-color has-grey-color\"><em>Gandhi L, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378:2078 \u2013 2092.<\/em><\/mark><\/li>\n\n\n\n<li><mark class=\"has-inline-color has-grey-color\"><em>Paz-Ares L, et al; Pembrolizumab Plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Eng J Med 2018;379:2040-2051.<\/em><\/mark><\/li>\n<\/ol>\n\n\n\n<p class=\"has-negative-1-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--654769ec17c633561a49c89d6cc41714\"><mark class=\"has-inline-color has-grey-color\"><em>Prima della prescrizione leggere l&#8217;informazione professionale completa disponibile sul sito web di Swissmedic (<a href=\"https:\/\/www.swissmedicinfo.ch\/\" target=\"_blank\" rel=\"noreferrer noopener\">www.swissmedicinfo.ch<\/a>).<\/em><\/mark><\/p>\n\n\n\n<p class=\"has-negative-1-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--2434c5f073446e4a9bb271327a05c982\"><mark class=\"has-inline-color has-grey-color\"><em>All&#8217;occorrenza, \u00e8 possibile richiedere copie delle pubblicazioni degli studi all&#8217;indirizzo che segue: \u00a9 MSD Merck Sharp &amp; Dohme AG, Werftestrasse 4, 6005 Lucerna, Svizzera. Tutti i diritti riservati.<a href=\"https:\/\/www.mymsd.ch\/it\/succinctstatement\/keytruda\/\">Fare clic qui per l&#8217;informazione professionale di KEYTRUDA (pembrolizumab).<\/a>CH-KEY-00323 | Maggio 2020<\/em><\/mark><\/p>\n","protected":false},"excerpt":{"rendered":"<p>LE IMMUNOTERAPIE MODIFICANO I PARADIGMI DI TRATTAMENTO NEI PAZIENTI CON NSCLC AVANZATO Note a pi\u00e8 di pagina *Pazienti che dopo [&hellip;]<\/p>\n","protected":false},"author":43910,"featured_media":0,"parent":0,"menu_order":12,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_mhh_sticky_footer_settings":{"entityId":0},"_mhh_sticky_footer_posts":"","_mhh_sticky_footer_expanded":false,"_mhh_mcn_text_direction":"","_mhh_mcn_language":"","_mhh_mcn_left_sidebar_settings":{"entityId":0},"_mhh_mcn_sidebar_settings":{"entityId":0},"mhh_mcn_side_navigation_style":{"fontSize":{"l":"","m":"","s":""},"lineHeight":{"l":1.5,"m":1.5,"s":1.5},"itemColor":"","hoverItemColor":"","currentItemColor":"","borderItemColor":"","backgroundItemHoverColor":"","themeColor":""},"_mhh_mcn_child_page_navigation":{"isActive":false,"isSticky":false},"hide_header":true,"show_top_bar":false,"hide_footer":false,"full_width_layout":false,"icon":null,"job_code":"","primary_tag":0,"editor_notices":[],"mconnectHideShareThis":false,"footnotes":"","mconnectIsArchiveTemplate":false,"mconnectArchiveFiltersDisabled":false,"mconnectArchiveLockAllPresetFilters":false,"mconnectArchiveHidePageSubmenu":false,"mconnectArchiveShowParentPageOnly":false,"mconnectArchiveDefaultOrder":"DESC","mconnectArchiveDefaultOrderBy":"date","mconnectArchivePostsPerPage":12,"mconnectArchivePostTypes":[],"mconnectArchiveAllowFilterBy":["category","tx-content-type","tx-product","tx-pathology","tx-active-ingredient","tx-therapeutic-area"],"mconnectArchiveTaxonomyOrder":[],"mconnectArchiveFilterSorting":["active","is_keyword","is_date"],"mconnectArchiveContentItemStyle":{"showExcerpt":true,"showImage":true,"showIcon":false,"showPrimaryTag":true,"showBorder":false,"showDates":false,"showCta":true,"isCard":false,"hasBackground":false,"showMetadata":true},"mconnectArchiveLayout":{"type":"list","hasFeatured":false},"mconnectDynamicTaxonomyEntities":[],"mconnectArchiveTerms_category":[],"mconnectArchiveAllowTerms_category":[],"mconnectArchiveTerms_tx-content-type":[],"mconnectArchiveAllowTerms_tx-content-type":[],"mconnectArchiveTerms_tx-product":[],"mconnectArchiveAllowTerms_tx-product":[],"mconnectArchiveTerms_tx-pathology":[],"mconnectArchiveAllowTerms_tx-pathology":[],"mconnectArchiveTerms_tx-active-ingredient":[],"mconnectArchiveAllowTerms_tx-active-ingredient":[],"mconnectArchiveTerms_tx-therapeutic-area":[],"mconnectArchiveAllowTerms_tx-therapeutic-area":[],"mconnectArchiveAllowTerms_dynamic-taxonomy":[],"mconnectArchiveLegacyDefaultTermsApplied":false,"mconnectContentUpdatesPerPage":10,"mconnectContentUpdatesViewMoreUrl":"","mconnectContentUpdatesTerms_tx-content-type":[],"mconnectContentUpdatesTerms_tx-product":[],"mconnectContentUpdatesTerms_tx-pathology":[],"mconnectContentUpdatesTerms_tx-active-ingredient":[],"mconnectContentUpdatesTerms_tx-therapeutic-area":[],"sidebar_toogle":0,"sidebar_toogle_notification_warning":true,"sidebar_toogle_notification_alert":true,"content_expiration_sidebar_date":"","content_expiration_sidebar_expired_post_status":"","content_expiration_sidebar_redirection":""},"categories":[279],"tags":[],"ga4_page_audience":[],"ga4_page_birn_id":[],"ga4_page_branding":[501],"ga4_page_businessunit":[507],"ga4_page_campaign":[],"ga4_page_content_purpose":[],"ga4_page_customer_journey_stage":[],"ga4_page_customer_specialty":[],"ga4_page_experience":[],"ga4_page_indication":[],"ga4_page_material_intent":[713],"ga4_page_product":[],"ga4_page_region":[],"ga4_page_therapeuticarea":[],"tx-therapeutic-area":[280],"tx-product":[270],"tx-pathology":[],"tx-content-type":[278],"tx-active-ingredient":[],"access":[],"user_status":[],"user_role":[],"class_list":["post-11546","page","type-page","status-publish","hentry","category-campaign"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Il miglior trattamento - MyMSD.ch IT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.mymsd.ch\/it\/best-treatment-first\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Il miglior trattamento - MyMSD.ch IT\" \/>\n<meta property=\"og:description\" content=\"LE IMMUNOTERAPIE MODIFICANO I PARADIGMI DI TRATTAMENTO NEI PAZIENTI CON NSCLC AVANZATO Note a pi\u00e8 di pagina *Pazienti che dopo [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mymsd.ch\/it\/best-treatment-first\/\" \/>\n<meta property=\"og:site_name\" content=\"MyMSD.ch IT\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-22T13:24:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.mymsd.ch\/it\/best-treatment-first\/\",\"url\":\"https:\/\/www.mymsd.ch\/it\/best-treatment-first\/\",\"name\":\"Il miglior trattamento - MyMSD.ch IT\",\"isPartOf\":{\"@id\":\"https:\/\/www.mymsd.ch\/it\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.mymsd.ch\/it\/best-treatment-first\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.mymsd.ch\/it\/best-treatment-first\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png\",\"datePublished\":\"2021-06-17T14:49:48+00:00\",\"dateModified\":\"2025-05-22T13:24:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.mymsd.ch\/it\/best-treatment-first\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.mymsd.ch\/it\/best-treatment-first\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.mymsd.ch\/it\/best-treatment-first\/#primaryimage\",\"url\":\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png\",\"contentUrl\":\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.mymsd.ch\/it\/best-treatment-first\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.mymsd.ch\/it\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Il miglior trattamento\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.mymsd.ch\/it\/#website\",\"url\":\"https:\/\/www.mymsd.ch\/it\/\",\"name\":\"MyMSD.ch IT\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.mymsd.ch\/it\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.mymsd.ch\/it\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.mymsd.ch\/it\/#organization\",\"name\":\"MSD Switzerland\",\"url\":\"https:\/\/www.mymsd.ch\/it\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.mymsd.ch\/it\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2023\/10\/cropped-myMSD-logo.png\",\"contentUrl\":\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2023\/10\/cropped-myMSD-logo.png\",\"width\":4084,\"height\":692,\"caption\":\"MSD Switzerland\"},\"image\":{\"@id\":\"https:\/\/www.mymsd.ch\/it\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Il miglior trattamento - MyMSD.ch IT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.mymsd.ch\/it\/best-treatment-first\/","og_locale":"it_IT","og_type":"article","og_title":"Il miglior trattamento - MyMSD.ch IT","og_description":"LE IMMUNOTERAPIE MODIFICANO I PARADIGMI DI TRATTAMENTO NEI PAZIENTI CON NSCLC AVANZATO Note a pi\u00e8 di pagina *Pazienti che dopo [&hellip;]","og_url":"https:\/\/www.mymsd.ch\/it\/best-treatment-first\/","og_site_name":"MyMSD.ch IT","article_modified_time":"2025-05-22T13:24:19+00:00","og_image":[{"url":"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png"}],"twitter_card":"summary_large_image","twitter_misc":{"Tempo di lettura stimato":"5 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.mymsd.ch\/it\/best-treatment-first\/","url":"https:\/\/www.mymsd.ch\/it\/best-treatment-first\/","name":"Il miglior trattamento - MyMSD.ch IT","isPartOf":{"@id":"https:\/\/www.mymsd.ch\/it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.mymsd.ch\/it\/best-treatment-first\/#primaryimage"},"image":{"@id":"https:\/\/www.mymsd.ch\/it\/best-treatment-first\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png","datePublished":"2021-06-17T14:49:48+00:00","dateModified":"2025-05-22T13:24:19+00:00","breadcrumb":{"@id":"https:\/\/www.mymsd.ch\/it\/best-treatment-first\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mymsd.ch\/it\/best-treatment-first\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.mymsd.ch\/it\/best-treatment-first\/#primaryimage","url":"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png","contentUrl":"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2021\/06\/banner_campaign_BTF_de.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.mymsd.ch\/it\/best-treatment-first\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mymsd.ch\/it\/"},{"@type":"ListItem","position":2,"name":"Il miglior trattamento"}]},{"@type":"WebSite","@id":"https:\/\/www.mymsd.ch\/it\/#website","url":"https:\/\/www.mymsd.ch\/it\/","name":"MyMSD.ch IT","description":"","publisher":{"@id":"https:\/\/www.mymsd.ch\/it\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mymsd.ch\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/www.mymsd.ch\/it\/#organization","name":"MSD Switzerland","url":"https:\/\/www.mymsd.ch\/it\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.mymsd.ch\/it\/#\/schema\/logo\/image\/","url":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2023\/10\/cropped-myMSD-logo.png","contentUrl":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2023\/10\/cropped-myMSD-logo.png","width":4084,"height":692,"caption":"MSD Switzerland"},"image":{"@id":"https:\/\/www.mymsd.ch\/it\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/pages\/11546","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/users\/43910"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/comments?post=11546"}],"version-history":[{"count":3,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/pages\/11546\/revisions"}],"predecessor-version":[{"id":102552,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/pages\/11546\/revisions\/102552"}],"wp:attachment":[{"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/media?parent=11546"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/categories?post=11546"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tags?post=11546"},{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_audience?post=11546"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_birn_id?post=11546"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_branding?post=11546"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_businessunit?post=11546"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_campaign?post=11546"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=11546"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=11546"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=11546"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_experience?post=11546"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_indication?post=11546"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_material_intent?post=11546"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_product?post=11546"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_region?post=11546"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=11546"},{"taxonomy":"tx-therapeutic-area","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tx-therapeutic-area?post=11546"},{"taxonomy":"tx-product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tx-product?post=11546"},{"taxonomy":"tx-pathology","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tx-pathology?post=11546"},{"taxonomy":"tx-content-type","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tx-content-type?post=11546"},{"taxonomy":"tx-active-ingredient","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tx-active-ingredient?post=11546"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/access?post=11546"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/user_status?post=11546"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/user_role?post=11546"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}